The Effect of Trimetazidine on Mitochondrial Function, Myocardial Performance, and Invasive Hemodynamics in Patients Diagnosed with Wild-Type Transthyretin Cardiac Amyloidosis.
Latest Information Update: 18 Mar 2024
At a glance
- Drugs Trimetazidine (Primary)
- Indications Cardiomyopathies; Transthyretin-related hereditary amyloidosis
- Focus Therapeutic Use
- 15 Mar 2024 Status changed from recruiting to completed.
- 22 Feb 2021 New trial record